poisar

Stocks · News reference

8-K filing — Quince Therapeutics, Inc. (QNCX)

SEC EDGAR

Filed: 2026-10-09 AccNo: 0001193125-26-418538 Size: 476 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

QNCX
Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

    Quince Therapeutics has rebranded to IRulya Therapeutics and will trade on Nasdaq under ticker 'IRLA' starting October 12, 2026. The company is focused on advancing LAM-001, an inhaled rapamycin formulation for pulmonary diseases including PH-ILD, BOS, and SAPH. New leadership has been appointed including CEO Brigette Roberts, M.D., and the company has a cash balance of $116 million expected to fund operations through end of 2028.

    QNCX